What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024
This mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from first-gener...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.23.176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|